Compare CIX & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIX | MGTX |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.6M | 1.0B |
| IPO Year | 1997 | 2018 |
| Metric | CIX | MGTX |
|---|---|---|
| Price | $37.14 | $10.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $27.75 |
| AVG Volume (30 Days) | 29.3K | ★ 815.0K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | 17.04 | ★ 33.02 |
| EPS | 1.06 | ★ 1.30 |
| Revenue | ★ $158,285,000.00 | $81,391,000.00 |
| Revenue This Year | N/A | $314.19 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.50 | ★ $8.49 |
| Revenue Growth | 8.46 | ★ 144.57 |
| 52 Week Low | $20.29 | $6.62 |
| 52 Week High | $40.29 | $15.35 |
| Indicator | CIX | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.71 | 27.75 |
| Support Level | $23.61 | $8.84 |
| Resistance Level | $40.29 | $11.85 |
| Average True Range (ATR) | 2.28 | 0.57 |
| MACD | -0.24 | -0.21 |
| Stochastic Oscillator | 35.98 | 8.33 |
Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's reportable operating segment includes Security Products and Marine Components. It generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Geographically, the company generates maximum revenue from the United States, followed by Canada, Mexico, and other markets.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.